UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported) December 10, 2010
 
Progenics Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
 
000-23143
 
13-3379479
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
         
777 Old Saw Mill River Road, Tarrytown, New York
 
10591
(Address of principal executive offices)
 
(Zip Code)
Registrant's telephone number, including area code (914) 789-2800
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 
 

 

Item 8.01.  Other Events.

Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) has exercised its option under its Termination and Transition Agreement with Wyeth Pharmaceuticals, a division of Wyeth LLC (a Pfizer Inc. subsidiary), to have Wyeth continue to commercialize RELISTOR® methylnaltrexone bromide in the United States through March 31, 2011.  As previously announced, Wyeth is continuing to market and sell RELISTOR ex-U.S. through the same date, subject to early transition options available to Progenics.

 
 




 
 

 

SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
                               PROGENICS PHARMACEUTICALS, INC.
                               By:  /s/ ROBERT A. MCKINNEY                            
                                   Robert A. McKinney
                                   Chief Financial Officer, Senior Vice President,
                                   Finance & Operations and Treasurer
 
 
 
Date:  December 10, 2010